What is Invictus Oncology?
Based in New Delhi, Invictus Oncology operates as a specialized biopharmaceutical enterprise dedicated to the discovery and development of novel therapeutics for oncology. Since its founding in 2011, the company has focused on bridging the gap between laboratory-based cancer research and clinical application. By prioritizing high-impact drug development, Invictus Oncology has established itself as a key player in the Indian life-sciences ecosystem, focusing on scalable solutions that address the complex biological challenges inherent in cancer treatment. The firm's market position is characterized by its integration of advanced scientific methodologies with a strategic focus on regional healthcare needs, positioning it as a vital contributor to the global oncology research community.
How much funding has Invictus Oncology raised?
Invictus Oncology has raised a total of $1.9M across 1 funding round:
Series A
$1.9M
Series A (2013): $1.9M with participation from Aarin Capital and Navam Capital
Key Investors in Invictus Oncology
Aarin Capital
Aarin Capital is a proprietary venture fund that invests in technology-intensive businesses across life-sciences, healthcare, and education, focusing on building sustainable companies from inception.
Navam Capital
Navam Capital is a venture capital firm specializing in seed and early-stage investments in frontier technology and science-driven innovation, providing patient capital to support long-term growth.
What's next for Invictus Oncology?
With the recent influx of capital, Invictus Oncology is well-positioned to accelerate its clinical trial phases and expand its research infrastructure. The strategic roadmap likely involves deepening its intellectual property portfolio and potentially pursuing collaborative partnerships to facilitate the commercialization of its lead candidates. As the company moves into its next phase of development, the focus will remain on achieving regulatory milestones and demonstrating the efficacy of its therapeutic pipeline. This capital deployment is expected to enhance the firm's competitive advantage, enabling it to scale its operations while maintaining the scientific rigor required to navigate the complex regulatory environment of the global biopharmaceutical industry.
See full Invictus Oncology company page
